KEGG   DRUG: Elranatamab
Entry
D12058                      Drug                                   
Name
Elranatamab (USAN);
Elranatamab (genetical recombination) (JAN);
Elranatamab-bcmm;
Elrexfio (TN)
Product
Formula
C6440H9958N1738O2010S49
Exact mass
145369.6742
Mol weight
145459.69
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYYMTWVRQA PGKGLEWVAF IRNRARGYTS
DHNPSVKGRF TISRDNAKNS LYLQMNSLRA EDTAVYYCAR DRPSYYVLDY WGQGTTVTVS
SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKCRVRCPRC PAPPVAGPSV
FLFPPKPKDT LMISRTPEVT CVVVAVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPS SIEKTISKTK GQPREPQVYT LPPSREEMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS DGSFFLYSRL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
(heavy chain)
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYPMSWVRQA PGKGLEWVSA IGGSGGSLPY
ADIVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARYW PMDIWGQGTL VTVSSASTKG
PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCEVE CPECPAPPVA GPSVFLFPPK
PKDTLMISRT PEVTCVVVAV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL
TVVHQDWLNG KEYKCKVSNK GLPSSIEKTI SKTKGQPREP QVYTLPPSRE EMTKNQVSLT
CEVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS
VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIVMTQSPDS LAVSLGERAT INCKSSQSLF NVRSRKNYLA WYQQKPGQPP KLLISWASTR
ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCKQSYDL FTFGSGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLMY DASIRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYQSWPLTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H98, H135-L219, H148-H204, H223-h217, H227-h221, H230-h224, H261-H321, H367-H425, h22-h96, h129-l215, h142-h198, h255-h315, h361-h419, L23-L94, L139-L199, l23-l89, l135-l195)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01FX32
Product: D12058<JP/US>
Efficacy
Antineoplastic
  Disease
Multiple myeloma [DS:H00010]
  Type
Monoclonal antibody
Target
CD3E [HSA:916] [KO:K06451]
  Pathway
hsa04640  Hematopoietic cell lineage
hsa04660  T cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX32 Elranatamab
      D12058  Elranatamab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-CD3/BCMA Antibodies
    Elranatamab
     D12058  Elranatamab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D12058  Elranatamab (USAN); Elranatamab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3E
     D12058  Elranatamab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12058
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12058
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12058
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12058
Other DBs
CAS: 2408850-14-4
PubChem: 497620471
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system